

Press release

Lille, 4th November 2021

AI biotech Oncocross partners with 4P-Pharma, a France based biotech.

Lille, 4th November 2021 - Oncocross, a Korea-based AI biotech specializing in drug development, announced that they executed a research collaboration agreement with 4P-Pharma, a France-based biotech at the Institut Pasteur de Lille located in Lille, France on 2021, October 25th (local time) last week. The two companies signed a collaboration agreement based on mutual trust to develop an AI platform-based treatment for systemic scleroderma, a rare autoimmune disease affecting the skin and internal organs that has no approved treatment in the market.

Oncocross, a leading biotech in Korea, utilizes AI platform to identify new disease indications for new drug candidates or existing drugs based on transcriptome database and is collaborating with leading global/Korean pharmaceutical companies and hospitals. Oncocross exhibits approximately 40% accuracy from *in silico* AI screening to *in vivo* validation. Last year, the company licensed out one of the pipelines, a drug combination for sarcopenia, to a Korean pharmaceutical company, which recorded the first licensing agreement of any AI-screened drug candidate in the country.


4P-Pharma is a clinical-stage biotech in France, specializing in the sourcing of early-stage therapeutics addressing high unmet medical needs, and the acceleration of their development to the clinic. 4P-Pharma has a proven expertise, the company has already pre-evaluated more than 300 projects, a technical due diligence has been carried out on more than 20 of them in 4P-Pharma's Research and Development (R&D) laboratory at the Institut Pasteur de Lille. Two are now incorporated in clinical-stage asset centric companies owned by 4P-Pharma.

Part of this partnership, Oncocross will use the RAPTOR AI, an AI platform developed by Oncocross, to screen and discover drug candidates. 4P-Pharma will establish a R&D maturation program and jointly agreed upon, to further characterize the candidate and demonstrate its potential to treat systemic scleroderma. Together, the two companies will join their expertise to bring an innovative therapeutic agent to the patients affected by this rare disease.

Dr. Yirang Kim, CEO of Oncocross, mentioned that "we are very excited about this collaboration with 4P-Pharma, where we can put together our AI platform technology and 4P-Pharma's R&D expertise to tackle and overcome this rare disease." Dr. Revital Rattenbach, chairwoman of 4P-Pharma said "This research collaboration agreement with Oncocross is an important opportunity to successfully develop an innovative therapy rapidly. It underlines our shared commitment to bring breakthrough solutions to patients."

Press release

Lille, 4th November 2021



Dr. Yirang Kim, CEO of Oncocross, and Dr. Revital Rattenbach, chairwoman of 4P-Pharma, celebrating the signature a research collaboration agreement between Oncocross and 4P-Pharma in Lille (France).

About Oncocross

Oncocross is a Seoul based AI biotechnology company specializing in drug development based on transcriptome database. Oncocross partners with pharmaceutical companies to develop treatments for intractable and rare disease both in oncology and non-oncology space by i) identifying the optimal indications of NCE under development, ii) identifying the proper indications for clinical stage failed compounds, iii) screening combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) screening the optimal drug candidate for selected disease indication.

Website: www.oncocross.com

LinkedIn: www.linkedin.com/company/oncocross-co-ltd

About 4P-Pharma

4P-Pharma is a French clinical-stage biotechnology company, located at the Institut Pasteur de Lille, specializing in the sourcing and acceleration of early-stage therapeutic molecules addressing unmet medical needs. 4P-Pharma aims to detect the most promising innovations from partners (i.e. academic institutions, biotech companies and TTOs) and performs in-house technological due-diligence applying stringent industry criteria. 4P-Pharma gathers all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision to bring innovations to clinical phases. Since the foundation of 4P-Pharma, in 2014, more than 300 molecules have been pre-evaluated, a technological due diligence has been carried out on more than 20 of them. Two are now incorporated in clinical-stage asset centric companies owned by 4P-Pharma.

Website: www.4p-pharma.com

LinkedIn: www.linkedin.com/company/4p-pharma

Twitter: @4P_Pharma